Pediatric Moyamoya Biomarkers: Narrowing the Knowledge Gap

Laura L Lehman1, Matsanga Leyila Kaseka2, Jeffery Stout3

  • 1Department of Neurology, Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Insights

Moyamoya disease, a progressive cerebrovascular disorder, requires better biomarkers for diagnosis and risk assessment in children. Identifying these biomarkers is crucial for determining optimal treatment, including revascularization surgery.

Area of Science:

  • Neurology
  • Vascular Biology
  • Pediatric Medicine

Background:

  • Moyamoya disease is a progressive cerebrovascular disorder characterized by stenosis in major cerebral arteries.
  • It leads to the formation of collateral vessels and increases the risk of ischemic events like stroke and TIA in children.
  • Cognitive decline can occur even without overt clinical symptoms.

Approach:

  • This review synthesizes current knowledge on pediatric moyamoya biomarkers.
  • It examines neurologic, cognitive, neuroimaging, genetic, and biologic markers.
  • Gaps in research are identified to guide future investigations.

Key Points:

  • Biomarkers are essential for accurate diagnosis and risk stratification in pediatric moyamoya.
  • Current standard care for symptomatic moyamoya involves revascularization surgery.
  • The role of revascularization in asymptomatic moyamoya remains debated, highlighting the need for better predictive tools.

Conclusions:

  • Further research into pediatric moyamoya biomarkers is critical.
  • Identifying reliable biomarkers will aid in personalized treatment strategies and surgical candidate selection.
  • Understanding disease severity and ischemic risk through biomarkers can improve patient outcomes.